文献速递青光眼眼底病与葡萄膜炎

Aurolab房水引流植入物治疗新生血管性青光眼的中期结局

Intermediate-term outcomes of the Aurolab aqueous drainage implant in neovascular glaucoma.
PubMed 文献 · Br J Ophthalmol · 2021-09-29

该研究纳入85例新生血管性青光眼(NVG)患眼,评估非阀式Aurolab房水引流植入物(AADI)的中期疗效。2年随访时眼压和降眼压药物数量显著下降,但累积手术失败率从1年的3.1%升至2年的33.8%,视力亦显著下降。开放房角患眼失败风险可能较低。

要点

  • AADI术后2年眼压从36.8 mmHg降至15.8 mmHg,降眼压药物从3.4种减至1.5种。
  • 2年累积手术失败率为33.8%(95%CI 20.4%–52.5%),约三分之一患眼失败。
  • 开放房角患眼失败风险较低(HR 0.17,95%CI 0.10–1.03,p=0.09),但未达统计学显著。

核心结论

  • 约三分之一接受AADI的NVG患眼在2年随访后失败,与其他系列相似。
  • 在NVG开放房角阶段早期植入AADI可能获得更好结果。

研究设计与样本

  • 回顾性纳入连续接受AADI且随访至少2年的NVG患眼。
  • 共纳入85例患者的85只患眼,平均年龄61.2±9.3岁。

主要发现

  • 最常见病因为增殖性糖尿病视网膜病变(n=43)和视网膜中央静脉阻塞(n=24)。
  • 眼压从基线36.8±12.5 mmHg降至2年时15.8±7.5 mmHg(p<0.001)。
  • 降眼压药物数量从3.4±0.8种减少至1.5±1.1种(p<0.001)。
  • 累积失败率从1年3.1%(95%CI 1.1%–11.8%)升至2年33.8%(95%CI 20.4%–52.5%)。
  • 最小分辨角对数视力从0.98±0.7下降至2年时1.8±1.0(p<0.001)。

关键数值与推荐

  • 手术失败定义:眼压>21 mmHg或较基线下降<20%、眼压≤5 mmHg、因青光眼或并发症再手术、或丧失光感。
  • 多变量分析显示开放房角患眼失败风险较低(HR 0.17,95%CI 0.10–1.03,p=0.09)。

临床怎么用

  • AADI可有效降低NVG患眼眼压并减少降眼压药物使用。
  • 需告知患者2年内约三分之一患眼可能失败且视力可能下降。
  • 考虑在NVG开放房角阶段早期植入AADI以改善预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the outcomes of the non-valved Aurolab aqueous drainage implant (AADI) in neovascular glaucoma (NVG). METHODS: Data of consecutive patients with NVG who underwent AADI and had a minimum follow-up of 2 years were included. The primary outcome measure was the cumulative rate of surgical failure defined as intraocular pressure (IOP) >21 mm Hg or reduced <20% below baseline, IOP ≤5 mm Hg, reoperation for glaucoma or a complication, or loss of light perception vision. RESULTS: We included 85 eyes of 85 patients with NVG, with a mean age of 61.2±9.3 years. The most common aetiologies were proliferative diabetic retinopathy (n=43) and central retinal vein occlusion (n=24). The mean IOP decreased from 36.8±12.5 mm Hg at baseline to 15.8±7.5 mm Hg at 2-year follow-up (p<0.001) and the number of IOP-lowering medications reduced from 3.4±0.8 to 1.5±1.1 (p<0.001). The cumulative rate of failure increased from 3.1% (95% CI 1.1% to 11.8%) at 1 year to 33.8% (95% CI 20.4% to 52.5%) at 2 years. Multivariable analysis showed that eyes with open angles had a lower risk of failure (HR 0.17, 95% CI 0.10 to 1.03, p=0.09). The logarithm of minimum angle of resolution visual acuity declined from 0.98±0.7 to 1.8±1.0 at 2 years (p<0.001). CONCLUSION: Approximately one-third of NVG eyes that received the AADI failed after 2 years of follow-up similar to other series. Early AADI implantation at the open angle stage of NVG may yield better results.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gnanavelu S, Puthuran GV, Chiranjeevi KP, et al. Intermediate-term outcomes of the Aurolab aqueous drainage implant in neovascular glaucoma. Br J Ophthalmol. 2021. PMID: 34588180. doi:10.1136/bjophthalmol-2021-319999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。